Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
December 15, 2005, Somaxon Pharmaceuticals, Inc. Announces Initial Public Offering
SAN DIEGO, CA – December 15, 2005 - Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares of common stock are being offered by the company. Somaxon has granted to the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price to cover over-allotments, if any. (pdf)
October 7, 2005, Somaxon Pharmaceuticals, Inc., Files for Initial Public Offering
SAN DIEGO , CA – Somaxon Pharmaceuticals, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission relating to an initial public offering of its common stock. All of the shares of common stock are to be offered by the company. (pdf)
September 20, 2005, Somaxon Pharmaceuticals, Inc., Initiates Second Phase III Clinical Trial of
SILENOR™, Product will be evaluated in long-term trial of elderly patients with primary chronic insomnia
San Diego, CA – Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that enrollment has begun in the second Phase III clinical trial of SILENOR™ (doxepin hydrochloride) for the treatment of insomnia. This multi-center, placebo-controlled Phase III clinical trial will evaluate the safety and efficacy of SILENOR™ over a three month period in elderly patients diagnosed with primary chronic insomnia. The primary endpoint of the trial is Wake After Sleep Onset (WASO), the sleep maintenance endpoint recommended by the FDA. Multiple secondary efficacy endpoints will be evaluated, both objectively and through patient-reported outcomes. (pdf)
June 9, 2005, Somaxon Pharmaceuticals, Inc., Initiates Phase III Clinical Trials of SILENOR™ in Patients with Insomnia, Product will be evaluated in adult and elderly patients with primary chronic insomnia and transient insomnia
San Diego, CA – Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of insomnia and other neuro-psychiatric disorders, today announced the initiation of patient enrollment in the first Phase III clinical trial of SILENOR™ (doxepin HCl) for insomnia. This multi-center, placebo-controlled Phase III study will evaluate the safety and efficacy of SILENOR™ in adults with primary, chronic insomnia. The primary endpoint of the study is a sleep maintenance measure, Wake After Sleep Onset (WASO) measured by polysomnography (PSG) in a sleep laboratory setting. Multiple secondary endpoints of sleep maintenance, onset and duration will be measured objectively and through patient reported outcomes. (pdf)
June 6, 2005, Somaxon Pharmaceuticals, Inc., Announces $65M Financing
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of insomnia and other neuro-psychiatric disorders, today announced that it has secured $65 million in committed financing through the private placement of its Series C preferred stock. MPM Capital Partners led the round, which included an additional new investor, Prospect Ventures. Existing Series A and B round investors also participated in the Series C preferred stock financing, including Domain Associates, LLC, BA Venture Partners, Montreux Equity Partners and CDIB BioScience Ventures. (pdf)
May 23, 2005, Somaxon Pharmaceuticals to Present at the UBS Global Pharmaceuticals Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals Inc, a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuro-psychiatric disorders, today announced that Kenneth Cohen, President and Chief Executive Officer will present a company overview at the UBS Global Pharmaceuticals Conference on Tuesday, May 24, 2005 at 2 p.m. (Eastern). (pdf)
April 21, 2005, Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients with Primary Sleep Maintenance Insomnia
SAN DIEGO, CA – Somaxon Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuro-psychiatric disorders, today announced that low-dose doxepin demonstrated statistically significant results in a Phase II dose-finding study in elderly patients with primary sleep maintenance insomnia. Low-dose doxepin demonstrated efficacy in its primary endpoint, Wake Time During Sleep (WTDS) at all doses studied, 1 mg, 3 mg and 6 mg. Low-dose doxepin also demonstrated efficacy in all secondary sleep maintenance endpoints as well as patient reported outcomes. In all dose groups, there were no differences in adverse events and no statistically significant next day residual effects with low-dose doxepin versus placebo. (pdf)
April 4, 2005, Somaxon Pharmaceuticals Appoints Philip Jochelson, M.D., as Sr. Vice President and Chief Medical Officer
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for the treatment of neuropsychiatric disorders, announced today that Philip Jochelson, M.D., has joined the company as Senior Vice President and Chief Medical Officer. Dr. Jochelson is responsible for leading all phases of the clinical development of Somaxon’s portfolio of compounds through NDA submission and approval. Additionally, Dr. Jochelson will be responsible for medical affairs and medical marketing support for commercialized products and will also lead the medical and clinical assessment of future in-licensing opportunities. (pdf)
March 10, 2005, Somaxon Pharmaceuticals to Present at the SG Cowen 25th Annual Health Care Conference on March 15
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for the treatment of neuropsychiatric disorders, today announced that Kenneth Cohen, president and chief executive officer, will present an overview of the company at the SG Cowen 25th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 15 for 12:30 p.m. ET at the Boston Marriot Copley Place Hotel. (pdf)
Februray 22, 2005, Somaxon Pharmaceuticals Licenses U.S. Rights to the Use of Oral Nalmefene from University of Miami for the Treatment of Nicotine Dependence
-- Company Intends To Initiate Proof-of-Principle Study in 2005--
SAN DIEGO , CA – Somaxon Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuropsychiatric disorders, today announced that it has licensed the rights to a U.S. patent on the use oral nalmefene hydrochloride for the treatment of nicotine dependence invented by Dr. Barbara Mason while at the University of Miami. (pdf)
January 6, 2005, Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-dose Doxepin in Adults with Primary Sleep Maintenance Insomnia
SAN DIEGO – Somaxon Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuro-psychiatric disorders, today announced that low-dose doxepin demonstrated statistically significant results in a Phase II dose-finding study in adults with primary sleep maintenance insomnia. There was no difference in adverse events or next day residual effects with low-dose doxepin versus placebo. (pdf)
January 5, 2005, Somaxon Pharmaceuticals to Present at the 23rd Annual JPMorgan Healthcare Conference
San Diego, CA -- Somaxon Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuro-psychiatric disorders, today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company overview at the 23rd Annual JPMorgan Health Care Conference on Monday, January 10, 2005, at 8:30am in the Elizabethan Room C&D at the Westin St. Francis Hotel in San Francisco. (pdf)
2007 | 2006 | 2004
